The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ezmekly (mirdametinib) for the treatment of ...

This article first appeared on GuruFocus. Merck KGaA (NYSE:MRK) is making a fresh push to rebuild its pharmaceutical firepower, and this time it is placing a multibillion-dollar bet on artificial ...

FRANKFURT (Reuters) -Germany's Merck KGaA on Thursday agreed to use Boston-based Valo Health's drug research services in a collaboration focused on Parkinson's and related diseases that is potentially ...

An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

Europe's universities and research institutes are particularly strong in biotech and pharmaceutical startups. A report from Dealroom shows that since 2022 there have been 244 academic spinouts in ...

By Annette Bakker The tragedy of rare disease is not only measured in lives lost—it’s also measured in lives that could have ...

Merck (MRK)’s stock surged by 41% over the past six months, driven not significantly by revenue, but rather by increased profits and heightened investor confidence. Following crucial Q3 earnings ...

GlobalCapital presents the nominations for its Syndicated Loan, Leveraged Finance and Private Debt Awards 2025. The Awards, ...